DOI: https://doi.org/10.22141/2224-1485.4.48.2016.76998

Telmisartan Shows Organoprotection and Reduces the Incidence of Adverse Cardiovascular Outcomes in Addition to the Antihypertensive Effect

A.V. Savustyanenko

Abstract


In previously published review the unique antihypertensive and metabolic properties of telmisartan were described. This drug lowers blood pressure well during the night and in the morning. It is characterized by a high homogeneity of the pressure drop during the day and the occasional missing the dose does not lead to serious consequences. High efficacy/safety ratio was noted for this drug, including in comparison with other antihypertensive agents. In addition, telmisartan reduced the severity of disorders of carbohydrate (insulin resistance) and lipid metabolism, reduced systemic inflammatory response and a tendency to thrombosis.
In this review of clinical trials organoprotective (vessels, heart, kidney) effects of telmisartan and its ability to prevent the development of adverse cardiovascular outcomes were justified.
Telmisartan improved vascular function by reducing endothelial dysfunction, arterial stiffness, and the thickness of the intima-media, increasing the number of endothelial progenitor cells, reducing the incidence of restenosis after stent placement and stabilization of atherosclerotic plaques in coronary arteries; improved cardiac function by reducing left ventricular hypertrophy, increasing left ventricular function, reducing the incidence of atrial fibrillation recurrence; improved renal function by reducing the severity of nephropathy; reduced the risk of adverse cardiovascular outcomes such as death from cardiovascular causes, incidence of nonfatal myocardial infarction and nonfatal stroke, hospitalization for heart failure, overall mortality.
Telmisartan is the only angiotensin receptor blocker recom-mended for a wide range of patients at high cardiovascular
risk.


Keywords


telmisartan; organoprotection; adverse cardiovascular outcomes

References


Савустьяненко А.В. Применение телмисартана при артериальной гипертензии и метаболическом синдроме // Артериальная гипертензия. — 2015. — № 3. — С. 67-77.

Anderson T.J. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk // The Canadian Journal of Cardio-logy. — 2006. — V. 22 (Suppl. B). — P. 72B-80B.

Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan / Wago T., Yoshimoto T., Akaza I. et al. // Hypertens. Res. — 2010. — V. 33, № 8. — P. 796-801.

Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function / Ono Y., Nakaya Y., Bando S. et al. // Int. Heart J. — 2009. — V. 50, № 1. — P. 73-83.

Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance / Perl S., Schmölzer I., Sourij H. еt al. // Int. J. Cardiol. — 2010. — V. 139, № 3. — P. 289-296.

Telmisartan improves endothelial function in patients with essential hypertension / Benndorf R.A., Appel D., Maas R. et al. // J. Cardiovasc. Pharmacol. — 2007. — V. 50, № 4. — P. 367-371.

Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels / Tomiyama H., Yamada J., Koji Y. et al. // Am. J. Hypertens. — 2007. — V. 20, № 12. — P. 1305-1311.

Renal and vascular protective effects of telmisartan in patients with essential hypertension / Morimoto S., Yano Y., Maki K., Sawada K. // Hypertens. Res. — 2006. — V. 29, № 8. — P. 567-572.

Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension / Li Y., Ma S.M., Du M. et al. // Zhonghua Xin Xue Guan Bing Za Zhi. — 2009. — V. 37, № 10. — P. 908-912.

Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients / Kinouchi K., Ichihara A., Sakoda M. et al. // Kidney Blood Press. Res. — 2010. — V. 33, № 4. — P. 304-312.

Uehara G., Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI) // J. Int. Med. Res. — 2008. — V. 36, № 5. — P. 1094-1102.

Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the Tromsø Study / Herder M., Johnsen S.H., Arntzen K.A., Mathiesen E.B. // Stroke. — 2012. — V. 43, № 7. — P. 1818-1823.

Carotid intima-media thickness as a biomarker of subclinical atherosclerosis / Bauer M., Caviezel S., Teynor A. et al. // Swiss Med. Wkly. — 2012. — V. 142. — Numb. of publ. w13705.

Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients / Hasegawa H., Takano H., Narumi H. et al. // Hypertens. Res. — 2011. — V. 34, № 11. — P. 1179-1184.

Antihypertensive and organ-protective action of a 36-week monotherapy with telmisartan in hypertensive patients / Petriĭ V.V., Sergushkina N.G., Brazhnik V.A., Makolkin V.I. // Ter. Arkh. — 2008. — V. 80, № 12. — P. 13-16.

Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study / Pelliccia F., Pasceri V., Cianfrocca C. et al. // Atherosclerosis. — 2010. — V. 210, № 2. — P. 510-515.

Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome / Porto I., Di Vito L., De Maria G.L. et al. // Am. J. Cardiol. — 2009. — V. 103, № 11. — P. 1500-1505.

Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril / Yokoyama J., Higuma T., Tomita H. et al. // Int. J. Cardiol. — 2009. — V. 132, № 1. — P. 114-120.

Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients / Terashima M., Kaneda H., Nasu K. et al. // JACC Cardiovasc. Interv. — 2012. — V. 5, № 2. — P. 182-190.

Telmisartan reduces neointima volume and pulse wave velo-city 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients / Hong S.J., Choi S.C., Ahn C.M. et al. // Heart. — 2011. — V. 97, № 17. — P. 1425-1432.

Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients / Hong S.J., Shim W.J., Choi J.I. et al. // Am. J. Cardiol. — 2007. — V. 100, № 11. — P. 1625-1629.

Rabbani R., Topol E.J. Strategies to achieve coronary arterial plaque stabilization // Cardiovasc Res. — 1999. — V. 41, № 2. — P. 402-417.

Effects of telmisartan on inflammatory cytokines and coronary plaque component as assessed on integrated backscatter intravascular ultrasound in hypertensive patients / Yamaguchi K., Wakatsuki T., Soeki T. et al. // Circ. J. — 2014. — V. 78, № 1. — P. 240-247.

Katholi R.E., Couri D.M. Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications // International Journal of Hypertension. — 2011. — Article ID 495349.

Boudina S., Abel E.D. Diabetic cardiomyopathy, causes and effects // Reviews in endocrine & metabolic disorders. — 2010. — V. 11, № 1. — P. 31-39.

Chopra H.K. Cardiological Society of India: Cardiology Update 2014 // Publisher: JP Medical Ltd. — 2015. — 1298 p.

Verdecchia P. Pre-clinical and clinical experience of telmi-sartan in cardiac remodelling // J. Int. Med. Res. — 2005. — V. 33 (Suppl. 1). — P. 12A-20A.

Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: assessment by tissue Doppler imaging and carotid ultrasonography / Mizuguchi Y., Oishi Y., Miyoshi H. et al. // Echocardiography. — 2010. — V. 27, № 7. — P. 864-872.

Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging / Mizuguchi Y., Oishi Y., Miyoshi H. et al. // J. Hypertens. — 2009. — V. 27, № 9. — P. 1892-1899.

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study / Galzerano D., Tammaro P., del Viscovo L. et al. // Am. J. Hypertens. — 2005. — V. 18, № 12 (Pt. 1). — P. 1563-1569.

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease / Verdecchia P., Sleight P., Mancia G. et al. // Circulation. — 2009. — V. 120, № 14. — P. 1380-1389.

Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]) / Cowan B.R., Young A.A., Anderson C. et al. // Am. J. Cardiol. — 2009. — V. 104, № 11. — P. 1484-1489.

Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study / Symeonides P., Koulouris S., Vratsista E. et al. // Eur. J. Echocardiogr. — 2007. — V. 8, № 6. — P. 480-486.

Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril / Yokota T., Osanai T., Hanada K. et al. // Heart Vessels. — 2010. — V. 25, № 6. — P. 460 — 468.

Biomarkers in atrial fibrillation: a clinical review / Hijazi Z., Oldgren J., Siegbahn A. et al. // Eur. Heart J. — 2013. — V. 34, № 20. — P. 1475-1480.

Pan G., Zhou X., Zhao J. Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis // Cardiovasc. Ther. — 2014. — V. 32, № 4. — P. 184-188.

Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation / Fogari R., Mugellini A., Zoppi A. et al. // J. Cardiovasc. Pharmacol. Ther. — 2012. — V. 17, № 1. — P. 34-43.

Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size / Fogari R., Zoppi A., Maffioli P. et al. // Clin. Cardiol. — 2012. — V. 35, № 6. — P. 359-364.

A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients / Galzerano D., Di Michele S., Paolisso G. еt al. // J. Renin Angiotensin Aldosterone Syst. — 2012. — V. 13, № 4. — P. 496-503.

Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients / Du H., Fan J., Ling Z. et al. // Hypertension. — 2013. — V. 61, № 4. — P. 786-792.

Telmisartan decreases atrial electromechanical delay in patients with newly diagnosed essential hypertension / Sengul C., Ce-vik C., Ozveren O. et al. // J. Electrocardiol. — 2012. — V. 45, № 2. — P. 123-128.

Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy / Galetta F., Franzoni F., Fallahi P. et al. // Biomed. Pharmacother. — 2010. — V. 64, № 8. — P. 516-520.

QT dispersion: Clinical applications // http://www.uptodate.com — 2014.

Diagnosis and management of chronic kidney disease: a national clinical guideline // Scottish Intercollegiate Guidelines Network. — 2008. — http://www.sign.ac.uk

Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials / Takagi H., Yamamoto H., Iwata K. et al. // Int. J. Cardiol. — 2013. — V. 167, № 4. — P. 1443-1449.

Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients / Rodríguez-Pérez J.C., García-Bello M.A., Anabitarte-Prieto A. еt al. // Clin. Exp. Hypertens. — 2011. — V. 33, № 8. — P. 506-510.

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies / Aranda P., Segura J., Ruilope L.M. et al. // Am. J. Kidney Dis. — 2005. — V. 46, № 6. — P. 1074-1079.

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial / Vogt L., Navis G., Köster J. et al. // J. Hypertens. — 2005. — V. 23, № 11. — P. 2055-2061.

Barnett A.H. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study // Acta Diabetol. — 2005. — V. 42 (Suppl. 1). — P. S42-S49.

Mazerska M., Myśliwiec M.Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors // Adv. Med. Sci. — 2009. — V. 54, № 1. — P. 37-40.

Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study / Makino H., Haneda M., Babazono T. et al. // Hypertens. Res. — 2008. — V. 31, № 4. — P. 657-664.

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy / Bakris G., Burgess E., Weir M. et al. / Kidney Int. — 2008. — V. 74, № 3. — P. 364-369.

Antiproteinuric effects of angiotensin receptor blockers: telmi-sartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy / Galle J., Schwedhelm E., Pinnetti S. et al. // Nephrol. Dial Transplant. — 2008. — V. 23, № 10. — P. 3174-3183.

Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial // J. Am. Soc. Nephrol. — 2006. — V. 17, № 4 (Suppl. 2). — P. S132-S135.

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease / Nakamura T., Fujiwara N., Kawagoe Y. et al. // Eur. J. Clin. Invest. — 2010. — V. 40, № 9. — P. 790-796.

Renoprotective effects of telmisartan in patients with advanced chronic kidney disease / Tokunaga M., Kabashima N., Serino R. et al. // Clin. Nephrol. — 2010. — V. 73, № 2. — P. 139-146.

Renoprotective effect of telmisartan in patients with chronic kidney disease / Nakamura T., Inoue T., Sugaya T. et al. // Clin. Exp. Hypertens. — 2008. — V. 30, № 7. — P. 662-672.

Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency / Nakamura T., Inoue T., Suzuki T. et al. // Hypertens. Res. — 2008. — V. 31, № 5. — P. 841-850.

Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney di-sease / Rysavá R., Tesar V., Merta M. et al. // Blood Press. Monit. — 2005. — V. 10, № 4. — P. 207-213.

Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake / Ekinci E.I., Thomas G., Thomas D. et al. // Diabetes Care. — 2009. — V. 32, V. 8. — P. 1398-1403.

Schmieder R.E., Bakris G., Weir M.R.Telmisartan in incipient and overt diabetic renal disease // J. Nephrol. — 2011. — V. 24, № 3. — P. 263-273.

Effect of telmisartan on renal outcomes: a randomized trial / Mann J.F., Schmieder R.E., Dyal L. еt al. // Ann. Intern. Med. — 2009. — V. 151, № 1. — P. 1-10.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial / Mann J.F., Schmieder R.E., McQueen M. et al. // Lancet. — 2008. — V. 372, № 9638. — P. 547-553.

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies / Tobe S.W., Clase C.M., Gao P. et al. // Circulation. — 2011. — V. 123, № 10. — P. 1098-1107.

Telmisartan, ramipril, or both in patients at high risk for vascular events / ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. // N. Engl. J. Med. — 2008. — V. 358, № 15. — P. 1547-1559.

Scheen A.J., Krzesinski J.M. ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events // Rev. Med. Liege. — 2008. — V. 63, № 4. — P. 213 — 219.

New standards in hypertension and cardiovascular risk management: focus on telmisartan / Galzerano D., Capogrosso C., Di Michele S. et al. // Vasc. Health Risk Manag. — 2010. — V. 24, № 6. — P. 113-133.

Frampton J.E. Telmisartan: a review of its use in cardiovascular disease prevention // Drugs. — 2011. — V. 71, № 6. — P. 651-677.

Telmisartan for the reduction of cardiovascular morbidity and mortality / Verdecchia P., Angeli F., Gentile G. et al. // Expert Rev. Clin. Pharmacol. — 2011. — V. 4, № 2. — P. 151-161.

Ruilope L.M. Telmisartan for the management of patients at high cardiovascular risk // Curr. Med. Res. Opin. — 2011. — V. 27, № 8. — P. 1673-1682.




Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта